Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

Published:2019-09 Issue:9 Volume:30 Page:1479-1486
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Wang F.^ORCID,Wei X.L.,Wang F.H.,Xu N.,Shen L.,Dai G.H.,Yuan X.L.,Chen Y.,Yang S.J.,Shi J.H.,Hu X.C.,Lin X.Y.,Zhang Q.Y.,Feng J.F.,Ba Y.,Liu Y.P.,Li W.,Shu Y.Q.,Jiang Y.,Li Q.,Wang J.W.,Wu H.,Feng H.,Yao S.,Xu R.H.

Funder

National Key R&D Program of China

National Key Research and Development Program of China

Natural Science Foundation of Guangdong Province

National Natural Science Foundation of China

Science and Technology Program of Guangdong

Sun Yat-sen University Clinical Research 5010 Program

Young Physician Scientist Program of Sun Yat-sen University Cancer

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz197/29022332/mdz197.pdf

Reference18 articles.

1. Cancer statistics in China, 2015;Chen;CA Cancer J Clin,2016

2. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer;Wang;Cancer Commun (Lond),2019

3. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure);Kim;Ann Oncol,2016

4. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial;Muro;Lancet Oncol,2016

5. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial;Fuchs;JAMA Oncol,2018

Cited by 332 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uncovering the potential of APOD as a biomarker in gastric cancer: A retrospective and multi-center study;Computational and Structural Biotechnology Journal;2024-12

2. Eight types of RNA modification regulators define clinical outcome and immune response in gastric cancer;Heliyon;2024-09

3. Unlocking the Potential: Epstein-Barr Virus (EBV) in Gastric Cancer and Future Treatment Prospects, a Literature Review;Pathogens;2024-08-28

4. Recent developments in immunotherapy for gastrointestinal tract cancers;Journal of Hematology & Oncology;2024-08-09

5. Pan-cancer analysis of heterogeneity of tumor mutational burden and genomic mutation under treatment pressure;ESMO Open;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3